(Q45230221)

English

An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency

scientific article published in February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency (English)

1 reference

Europe PubMed Central

11 December 2017

1 reference

based on heuristic

inferred from title

J. Richard Thistlethwaite, Jr.

6

object named as

J Richard Thistlethwaite

1 reference

Europe PubMed Central

11 December 2017

author name string

V Ram Peddi

1

1 reference

Europe PubMed Central

11 December 2017

Stephen Jensik

2

1 reference

Europe PubMed Central

11 December 2017

Mark Pescovitz

3

1 reference

Europe PubMed Central

11 December 2017

John Pirsch

4

1 reference

Europe PubMed Central

11 December 2017

Scott H Adler

5

1 reference

Europe PubMed Central

11 December 2017

Flavio Vincenti

7

1 reference

Europe PubMed Central

11 December 2017

David J Cohen

8

1 reference

Europe PubMed Central

11 December 2017

publication date

1 February 2005

1 reference

Europe PubMed Central

11 December 2017

Clinical Transplantation

1 reference

Europe PubMed Central

11 December 2017

19

1 reference

Europe PubMed Central

11 December 2017

1

1 reference

Europe PubMed Central

11 December 2017

130-136

1 reference

Europe PubMed Central

11 December 2017

The natural history of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Conversion to sirolimus in solid organ transplantation: a Single-Center experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00314.X

21 January 2018

Identifiers

10.1111/J.1399-0012.2004.00314.X

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45230221&oldid=2070726319"